Show simple item record

dc.contributor.authorAnderson, Heatheren
dc.contributor.authorThatcher, Nicken
dc.contributor.authorRankin, Elaine Men
dc.contributor.authorWagstaff, Johnen
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-07-21T12:31:59Z
dc.date.available2010-07-21T12:31:59Z
dc.date.issued1983-01
dc.identifier.citationVAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. 1983, 19 (1):49-52 Eur J Cancer Clin Oncolen
dc.identifier.issn0277-5379
dc.identifier.pmid6687868
dc.identifier.doi10.1016/0277-5379(83)90397-8
dc.identifier.urihttp://hdl.handle.net/10541/108060
dc.description.abstractTwenty patients presenting with metastatic carcinoma from an unknown primary site were studied. All patients were treated with a triple chemotherapy regimen of vincristine, adriamycin and cyclophosphamide repeated at three-week intervals. The response rate was 50%, and the four patients achieving complete response are alive and disease-free at 13, 16, 36 and 39 months. Toxicity was minimal and the majority of patients' performance status improved with the chemotherapy. VAC chemotherapy is indicated for patients with metastases, particularly of soft tissues originating from a carcinoma from an unknown primary site.
dc.language.isoenen
dc.subjectCancer Metastasisen
dc.subject.meshAdult
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCyclophosphamide
dc.subject.meshDactinomycin
dc.subject.meshDrug Therapy, Combination
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshNeoplasm Metastasis
dc.subject.meshVincristine
dc.titleVAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign, Dept. of Medical Oncology, Manchester University and Christie Hospital & Holt Radium Institute, Wilmslow Road, Manchester M20 9BX, U.K.en
dc.identifier.journalEuropean Journal of Cancer & Clinical Oncologyen
html.description.abstractTwenty patients presenting with metastatic carcinoma from an unknown primary site were studied. All patients were treated with a triple chemotherapy regimen of vincristine, adriamycin and cyclophosphamide repeated at three-week intervals. The response rate was 50%, and the four patients achieving complete response are alive and disease-free at 13, 16, 36 and 39 months. Toxicity was minimal and the majority of patients' performance status improved with the chemotherapy. VAC chemotherapy is indicated for patients with metastases, particularly of soft tissues originating from a carcinoma from an unknown primary site.


Files in this item

This item appears in the following Collection(s)

Show simple item record